Carl Dambkowski Sells 5,500 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,500 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $84.84, for a total transaction of $466,620.00. Following the sale, the insider directly owned 208,398 shares of the company’s stock, valued at $17,680,486.32. This represents a 2.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, March 4th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The stock was sold at an average price of $71.06, for a total transaction of $390,830.00.
• On Wednesday, February 4th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $65.79, for a total transaction of $361,845.00.
• On Wednesday, January 7th, Carl Dambkowski sold 18,700 shares of Apogee Therapeutics stock. The stock was sold at an average price of $77.84, for a total value of $1,455,608.00.

Apogee Therapeutics Stock Performance

NASDAQ:APGE opened at $84.34 on Friday. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $85.94. The stock has a 50 day moving average of $71.40 and a two-hundred day moving average of $66.22. The firm has a market cap of $5.86 billion, a P/E ratio of -19.99 and a beta of 1.02.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 2nd. The company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.02. On average, research analysts forecast that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.

Institutional Trading of Apogee Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. purchased a new position in shares of Apogee Therapeutics during the 4th quarter worth $25,000. Los Angeles Capital Management LLC purchased a new stake in shares of Apogee Therapeutics in the fourth quarter valued at about $37,000. ANTIPODES PARTNERS Ltd grew its holdings in shares of Apogee Therapeutics by 41.2% in the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after purchasing an additional 246 shares during the period. Seven Fleet Capital Management LP acquired a new stake in Apogee Therapeutics during the fourth quarter worth about $136,000. Finally, Ensign Peak Advisors Inc purchased a new position in Apogee Therapeutics during the fourth quarter worth about $170,000. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on APGE. BTIG Research reaffirmed a “buy” rating and set a $137.00 target price on shares of Apogee Therapeutics in a research note on Monday, March 23rd. Jefferies Financial Group reiterated a “buy” rating and issued a $95.00 target price on shares of Apogee Therapeutics in a research report on Monday, February 2nd. Wolfe Research started coverage on shares of Apogee Therapeutics in a research note on Wednesday, January 7th. They issued a “peer perform” rating on the stock. Stephens initiated coverage on shares of Apogee Therapeutics in a research report on Tuesday, December 16th. They set an “overweight” rating and a $95.00 price target on the stock. Finally, Wall Street Zen cut shares of Apogee Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $110.79.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.